CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
August 2020—Becton Dickinson announced that the FDA granted emergency use authorization to the BD Veritor Plus System for Rapid Detection of SARS-CoV-2 Assay, a point-of-care diagnostic test for use with the BD Veritor Plus System.
BD clinical studies performed at more than 20 sites in the United States demonstrated that the test is capable of achieving 84 percent sensitivity and 100 percent specificity. The assay delivers results in 15 minutes.
The BD Veritor System offers customers real-time reporting capabilities through the BD Synapsys informatics solution, which provides users the ability to report data for disease monitoring and surveillance purposes.
Pages: 1 2